SynthesisFrontiers in cardiovascular medicine2026
Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis.
Synthesis in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current studies suggest a potential association between the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and atrial fibrillation (AF) recurrence after catheter ablation, but the findings remain controversial. Therefore, we conducted a meta-analysis to evaluate this association, aiming to provide evidence for clinical prevention and treatment. Methods: We systematically searched PubMed, Embase, Web of Science, Cochrane Library, and four Chinese databases (CNKI, WanFang, VIP, and CBM) up to June 10, 2026, for studies on the association between GLP-1RAs and AF recurrence following catheter ablation. Two researchers independently screened literature, extracted data and assessed study quality. Statistical analyses were performed using Review Manager 5.3 and R 4.6.0. Results: A total of seven studies involving 7,907 patients were included. The meta-analysis showed that the use of GLP-1RAs was associated with a reduced risk of AF recurrence after catheter ablation (HR = 0.52, 95%CI = 0.37-0.73, Conclusions: The use of GLP-1RAs may reduce the risk of AF recurrence after catheter ablation. However, the 95% prediction interval crossed the null value, indicating that this protective effect is not definitive. Given the limitations of this study, further high-quality randomized controlled trials are warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.